Geron stem cell therapy promising in the lab

An experimental stem cell therapy in Geron's pipeline produced some promising preclinical results for glioblastoma brain cancer and prostate cancer. Researchers say that imetelstat (also called GRN163L), was able to cross the blood/brain barrier and inhibited 60 percent to 70 percent of the tumors implanted in mice. The therapy is in multiple Phase I studies and is scheduled to begin Phase II trials later this year. Report

Suggested Articles

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me

Q32 Bio is working on treatments for autoimmune and inflammatory diseases that improve on systemic approaches.